Company profile
KYNTRA BIO, INC.
NASDAQ:KYNBBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ROXADUSTAT | phase3 | — | 6 | no active trials |
| PAMREVLUMAB | phase2 | — | 9 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (41)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01181245 | phase1 | completed | 2008-12-01 | 2014-05-01 | Kyntra Bio | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer |
| NCT00456053 | phase2 | completed | 2005-12-01 | — | Kyntra Bio | A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin |
| NCT01217632 | phase2 | terminated | 2010-08-01 | 2015-06-01 | Kyntra Bio | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection |
| NCT06842498 | phase2 | recruiting | 2026-02-22 | 2028-03-31 | Kyntra Bio | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| NCT02210559 | phase1_2 | completed | 2014-07-31 | 2021-12-15 | Kyntra Bio | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer |
FDA applications (0)
No records yet.